ObsEva IVF nolasiban drug flops in key European trial

Swiss-listed drugmaker ObsEva said on Thursday it is abandoning the current program for its drug prospect nolasiban after the agent aimed at boosting pregnancy following in-vitro fertilization (IVF) failed a late-stage study in Europe.

from Reuters: Health News https://ift.tt/2Cm0vxX